Sensus Healthcare to Participate in Two Upcoming Investor Conferences

BOCA RATON, Fla., Aug. 27, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, President and Chief Executive Officer, will participate at two investor conferences in September 2018, as follows:

Mr. Sardano's presentation at the H.C. Wainwright 20^th Annual Global Investment Conference will be webcast live and available for replay in the Investor Relations section of the Company's website at sensushealthcare.com. 

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.

Contact:
LHA Investor Relations 
Kim Sutton Golodetz
(212) 838-3777
[email protected]

SOURCE Sensus Healthcare

Related Links

http://www.sensushealthcare.com